TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) just unveiled an announcement.
CARsgen Therapeutics Holdings Ltd. announced the grant of 6,740,500 options under its Post-IPO Share Option Scheme to 348 grantees, representing approximately 1.17% of the total issued shares. The options have an exercise price of HK$20.99 per share and will vest over a period of four years, starting from September 18, 2026. This strategic move aims to incentivize employees and align their interests with the company’s long-term growth objectives, potentially enhancing CARsgen’s competitive positioning in the biotechnology sector.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$14.92 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd. operates in the biotechnology industry, focusing on the development of innovative CAR-T cell therapies for the treatment of cancer. The company is committed to advancing its research and development efforts to address unmet medical needs in the oncology sector.
Average Trading Volume: 2,550,196
Technical Sentiment Signal: Hold
Current Market Cap: HK$12.02B
For a thorough assessment of 2171 stock, go to TipRanks’ Stock Analysis page.